JOP20210125A1 - إيلاسيسترانت بالاشتراك مع أبيماسيكليب عند النساء المصابات بسرطان الثدي - Google Patents

إيلاسيسترانت بالاشتراك مع أبيماسيكليب عند النساء المصابات بسرطان الثدي

Info

Publication number
JOP20210125A1
JOP20210125A1 JOP/2021/0125A JOP20210125A JOP20210125A1 JO P20210125 A1 JOP20210125 A1 JO P20210125A1 JO P20210125 A JOP20210125 A JO P20210125A JO P20210125 A1 JOP20210125 A1 JO P20210125A1
Authority
JO
Jordan
Prior art keywords
breast cancer
elasistrant
apimasiclib
women
combination
Prior art date
Application number
JOP/2021/0125A
Other languages
Arabic (ar)
English (en)
Inventor
Charles Morris
Nina K Aragam
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of JOP20210125A1 publication Critical patent/JOP20210125A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JOP/2021/0125A 2018-11-30 2019-11-26 إيلاسيسترانت بالاشتراك مع أبيماسيكليب عند النساء المصابات بسرطان الثدي JOP20210125A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773960P 2018-11-30 2018-11-30
PCT/US2019/063239 WO2020112765A1 (en) 2018-11-30 2019-11-26 Elacestrant in combination with abemaciclib in women with breast cancer

Publications (1)

Publication Number Publication Date
JOP20210125A1 true JOP20210125A1 (ar) 2019-11-26

Family

ID=68966023

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0125A JOP20210125A1 (ar) 2018-11-30 2019-11-26 إيلاسيسترانت بالاشتراك مع أبيماسيكليب عند النساء المصابات بسرطان الثدي

Country Status (18)

Country Link
US (3) US20220117963A1 (https=)
EP (1) EP3886826A1 (https=)
JP (2) JP2022509262A (https=)
KR (1) KR20210097170A (https=)
CN (1) CN113164415A (https=)
AU (1) AU2019388900B2 (https=)
BR (1) BR112021010169A2 (https=)
CA (1) CA3120368A1 (https=)
EA (1) EA202191165A1 (https=)
IL (1) IL283502A (https=)
JO (1) JOP20210125A1 (https=)
MA (1) MA54293A (https=)
MX (1) MX2021005876A (https=)
MY (1) MY209833A (https=)
PH (1) PH12021551235A1 (https=)
SG (1) SG11202105455RA (https=)
UA (1) UA129403C2 (https=)
WO (1) WO2020112765A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
EP4037768B1 (en) 2019-10-01 2023-10-11 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2022106711A1 (en) * 2020-11-23 2022-05-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN114146182A (zh) * 2021-11-12 2022-03-08 深圳大学 Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250152679A (ko) * 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
AU2017235450A1 (en) * 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
WO2018017410A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer

Also Published As

Publication number Publication date
EP3886826A1 (en) 2021-10-06
WO2020112765A1 (en) 2020-06-04
MA54293A (fr) 2021-10-06
BR112021010169A2 (pt) 2021-08-17
MY209833A (en) 2025-08-07
JP2025094216A (ja) 2025-06-24
CN113164415A (zh) 2021-07-23
SG11202105455RA (en) 2021-06-29
KR20210097170A (ko) 2021-08-06
PH12021551235A1 (en) 2021-12-13
US20260014153A1 (en) 2026-01-15
EA202191165A1 (ru) 2021-09-21
AU2019388900B2 (en) 2025-09-04
CA3120368A1 (en) 2020-06-04
US20250268899A1 (en) 2025-08-28
AU2019388900A1 (en) 2021-06-10
JP2022509262A (ja) 2022-01-20
IL283502A (en) 2021-07-29
US20220117963A1 (en) 2022-04-21
MX2021005876A (es) 2021-07-16
UA129403C2 (uk) 2025-04-16

Similar Documents

Publication Publication Date Title
JOP20210125A1 (ar) إيلاسيسترانت بالاشتراك مع أبيماسيكليب عند النساء المصابات بسرطان الثدي
MX2024010140A (es) Nuevos metodos.
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2020002229A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
MX392408B (es) Tratamiento de cáncer gástrico usando terapias de combinación que comprenden irinotecán liposómico oxaliplatino, 5-fluoruracilo (y leucovorina).
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
CL2019003496A1 (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
WO2016051398A8 (en) Patient-specific immunotherapy for treating heterogeneous tumors
MX385425B (es) Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
NI201700024A (es) Tratamientos médicos a base de anamorelina
MX390945B (es) Compuestos para el tratamiento de tnbc.
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
PH12015502655A1 (en) Method
EP3644753A4 (en) METHODS FOR MAINTAINING AND IMPROVING RENAL FUNCTION IN PATIENTS WITH RENAL DISEASE AND STANDARD TREATMENT THERAPY
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
WO2017189906A8 (en) Immune-based treatment of kras-variant cancer patients
WO2018231799A8 (en) Methods of treating brain tumors using combination therapy
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
EA201892592A1 (ru) Лечение мелкоклеточного рака легких с помощью липосомального иринотекана
RU2014146031A (ru) Фармацевтический гель на основе доксорубицина и кремнийорганических наночастиц-ниосом для лечения рака кожи